SCHEMBL164897

SCHEMBL164897

NC(=O)c1ccc(O)cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.46
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA7 P43166 4/20 0.46
CA9 Q16790 4/20 0.46
CA14 Q9ULX7 4/20 0.46
CES2 O00748 1/20 0.46
ALDH1A1 P00352 4/20 0.45
TSHR P16473 2/20 0.45
GFER P55789 1/20 0.44
PARP1 P09874 1/20 0.43
LCK P06239 1/20 0.43
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
IKBKB O14920 1/20 0.41
ESRRB O95718 1/20 0.41
ESRRG P62508 1/20 0.41
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28033110 0.84 PPM1B (0.54) ALDH1A1GFERMAPTKDM4EHPGD
SCHEMBL440293 0.82 ALDH1A1 (0.61) CA12CA1CA2CA7CA9
SCHEMBL562543 0.82 IKBKB (0.55) CA12CA1CA2CA7CA9
SCHEMBL1805264 0.81 CES2 (0.50) CA12CA1CA2CA7CA9
SCHEMBL9256689 0.80 HSD17B1 (0.46) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL9797011 0.80 ALDH1A1 (0.59) CA12CA1CA2CA7CA9
SCHEMBL12583326 0.79 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL1329143 0.79 CES2 (0.67) CA12CA1CA2CA7CA9
SCHEMBL5369877 0.79 CES2 (0.67) CA12CA1CA2CA7CA9
SCHEMBL7409099 0.79 MAPT (0.48) ALDH1A1TSHRGFERMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119050430-B Rare earth-vanadium redox flow battery 湖南省银峰新能源有限公司 2025-03-11 CN claimed
CN-119050430-A Rare earth-vanadium redox flow battery 湖南省银峰新能源有限公司 2024-11-29 CN claimed
EP-0048222-B1 STABILISATION OF THERMOPLASTICS THAT CONTAIN CHLORINE WITH M-AMINO PHENOLS CIBA-GEIGY AG (CH) 1984-12-27 EP claimed
US-4385147-A Stabilization of chlorine-containing thermoplastics with m-aminophenol derivatives CIBA-GEIGY CORPORATION (US) 1983-05-24 US claimed
EP-0048222-A1 Stabilisation of thermoplastics that contain chlorine with m-amino phenols CIBA-GEIGY AG (CH) 1982-03-24 EP claimed
US-12459895-B2 MEK inhibitors and uses thereof Ikena Oncology, Inc. (US) 2025-11-04 US disclosed
EP-4532470-A1 MEK INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2025-04-09 EP disclosed
CN-119768393-A MEK inhibitors and uses thereof 医肯纳肿瘤学公司 2025-04-04 CN disclosed
CN-119050430-B Rare earth-vanadium redox flow battery 湖南省银峰新能源有限公司 2025-03-11 CN disclosed
CN-119050430-B Rare earth-vanadium redox flow battery 湖南省银峰新能源有限公司 2025-03-11 CN disclosed
CN-119050430-A Rare earth-vanadium redox flow battery 湖南省银峰新能源有限公司 2024-11-29 CN disclosed
CN-119050430-A Rare earth-vanadium redox flow battery 湖南省银峰新能源有限公司 2024-11-29 CN disclosed
EP-2401267-A1 JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2012-01-04 EP disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20100317659-A1 JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2010-12-16 US disclosed
WO-2010099379-A1 JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2010-09-02 WO disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
EP-0048222-B1 STABILISATION OF THERMOPLASTICS THAT CONTAIN CHLORINE WITH M-AMINO PHENOLS CIBA-GEIGY AG (CH) 1984-12-27 EP disclosed
US-4385147-A Stabilization of chlorine-containing thermoplastics with m-aminophenol derivatives CIBA-GEIGY CORPORATION (US) 1983-05-24 US disclosed
EP-0048222-A1 Stabilisation of thermoplastics that contain chlorine with m-amino phenols CIBA-GEIGY AG (CH) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 CA12 3232/4885CA1 3728/4885CA2 3954/4885
US-12459895-B2 MEK inhibitors and uses thereof BRAF, NRAS, KRAS CA12 4423/4885CA1 4614/4885CA2 4019/4885
US-20100317659-A1 JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF JAK2, JAK3, JAK1 CA12 4682/4885CA1 4854/4885CA2 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.